Yale Depression Research Program, Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA.
Medical Scientist Training Program, Yale School of Medicine, New Haven, CT, USA; Interdepartmental Neuroscience Program, Yale School of Medicine, New Haven, CT, USA.
Drug Discov Today. 2023 Dec;28(12):103818. doi: 10.1016/j.drudis.2023.103818. Epub 2023 Nov 2.
Psychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic agents for psychiatric disorders has recently re-emerged. Here, we review progress in the development of psychedelic compounds that have potential therapeutic effects as well as the safety concerns. We include psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and the entactogen 3,4-methyl-enedioxy-methamphetamine (MDMA). We also review the potential interactive effects these compounds can have with psychotherapeutic approaches. We provide a cutting-edge review of active and recently completed clinical trials based on the published literature (from MEDLINE), published abstracts at citable conferences, clinical trials from the US Clinical Trials registry (clinicaltrials.gov) and media press releases.
精神障碍是全球范围内导致残疾的最大原因。最近，人们对迷幻物质作为治疗精神障碍的潜在药物重新产生了兴趣。在这里，我们回顾了具有潜在治疗效果和安全性问题的迷幻化合物的开发进展。我们包括了裸盖菇素、N,N-二甲基色胺（DMT）、麦角酸二乙基酰胺（LSD）和致幻剂 3,4-亚甲二氧基甲基苯丙胺（MDMA）。我们还回顾了这些化合物与心理治疗方法可能具有的潜在相互作用。我们根据已发表的文献（来自 MEDLINE）、可引用会议的已发表摘要、美国临床试验注册处（clinicaltrials.gov）的临床试验和媒体新闻稿，对基于现有临床数据的积极和最近完成的临床试验进行了前沿回顾。
